TD Asset Management Inc. lifted its holdings in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 134.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 36,980 shares of the biopharmaceutical company’s stock after acquiring an additional 21,180 shares during the quarter. TD Asset Management Inc. owned 0.05% of Dicerna Pharmaceuticals worth $542,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in DRNA. BlackRock Inc. increased its holdings in Dicerna Pharmaceuticals by 46.0% in the fourth quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock valued at $46,300,000 after buying an additional 1,364,155 shares during the last quarter. Vanguard Group Inc. increased its holdings in Dicerna Pharmaceuticals by 40.7% in the third quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock valued at $30,265,000 after buying an additional 573,197 shares during the last quarter. RTW Investments LP increased its holdings in Dicerna Pharmaceuticals by 8.2% in the fourth quarter. RTW Investments LP now owns 5,907,088 shares of the biopharmaceutical company’s stock valued at $63,147,000 after buying an additional 445,964 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Dicerna Pharmaceuticals by 3,144.4% in the first quarter. JPMorgan Chase & Co. now owns 445,722 shares of the biopharmaceutical company’s stock valued at $6,530,000 after buying an additional 431,984 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at approximately $4,501,000. 85.76% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently commented on the company. ValuEngine raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. BidaskClub downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. SunTrust Banks reduced their price objective on Dicerna Pharmaceuticals to $20.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, Citigroup reiterated a “buy” rating and set a $30.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Friday, May 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.38.
Shares of NASDAQ:DRNA traded down $0.14 on Monday, reaching $15.61. 287,800 shares of the company traded hands, compared to its average volume of 487,615. Dicerna Pharmaceuticals Inc has a fifty-two week low of $9.31 and a fifty-two week high of $17.98. The firm has a 50 day simple moving average of $13.61. The stock has a market cap of $1.08 billion, a PE ratio of -13.01 and a beta of 2.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative net margin of 1,284.93% and a negative return on equity of 52.17%. The company had revenue of $3.11 million for the quarter, compared to analyst estimates of $10.59 million. As a group, research analysts forecast that Dicerna Pharmaceuticals Inc will post -1.35 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read More: Why are percentage decliners important?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.